Introduction:
The Swiss biotech sector experienced robust growth in 2023, with revenues increasing by CHF500m to CHF7.3bn. Capital investment also grew to CHF2bn. The Swiss Biotech Report 2024 shows that this growth is partly due to collaboration with Big Pharma and an increase in product sales aided by regulatory approvals. Despite a challenging financing environment, some privately financed biotech companies were able to secure significant funding in 2023. The report also highlights the high export share of the Swiss life sciences and biotech industry.
- The Swiss biotech sector recorded CHF7.3bn in revenues in 2023, surpassing pre-pandemic levels.
- Collaboration with Big Pharma and an increase in product sales contributed to the sector’s growth.
- Oculis SA and MoonLake Immunotherapeutics AG received the largest capital inflows among public Swiss companies.
- Privately financed biotech companies, such as Noema Pharma AG and Alentis Therapeutics AG, secured significant funding.
- The Swiss life sciences and biotech industry has a high export share and is of international interest.
Conclusion:
The Swiss biotech sector has experienced strong growth in 2023, surpassing pre-pandemic levels, due to collaboration with Big Pharma and successful product sales. Despite a challenging financing environment, both public and private Swiss biotech companies have secured significant funding. The industry’s high export share and international interest highlight its importance in the global biotech sector. Further success in the sector will depend on continued collaboration, regulatory approvals, and funding opportunities.
